This article is available online at http://www.jlr.org concentrations that were 32% lower for HDL2 and 8% lower for HDL3 (the less buoyant particles) compared with those who did not develop CHD ( 3 ).Gofman's initial observation gave rise to studies by others on the potential clinical utility of HDL2 and HDL3 measurements. Rather than employing Gofman's original methodology, they measured HDL2-and HDL3-cholesterol by precipitation and HDL size classes by nuclear magnetic resonance (NMR) or, more rarely, ultracentrifugation. Many studies showed that high HDL2 was associated with lower CHD risk ( 4-10 ); however, the independent effects of HDL2 and HDL3 on CHD risk remained inconclusive ( 5, 7-10 ). Currently, the National Cholesterol Education Program Adult Treatment Panel (ATP-III) guidelines ( 11 ) state that "although small studies suggest greater predictive power of one or another HDL component, their superiority over HDL-cholesterol has not been demonstrated in large, prospective studies. Consequently, ATP III does not recommend the routine measurement of HDL subspecies in CHD risk assessment." However, the clinical utility of HDL subclasses may be underappreciated in part due to the limitations of these alternative methods to adequately characterize HDL heterogeneity ( 12-16 ).Between 1954 and 1956, John Gofman created a cohort of 1,905 men in whom lipoproteins were measured by analytic ultracentrifugation ( 3 ). Our rediscovery of Gofman's original data enabled us to assess the relationships of lipoprotein mass concentrations to CHD during 29-year follow-up ( 17 ). Those analyses showed that i ) the lowest quartile of HDL2-mass increased the men's risks of fatal plus nonfatal CHD by 38% and their risks of premature CHD (age р 65 years) by 61% when adjusted for traditional risk factors, ii ) the HDL2-CHD risk relationship remained signifi cant when adjusted for HDL3, and iii ) the risk reduction per mg/dl of HDL-mass was signifi cantly greater Abstract To assess the relationships of lipoprotein mass concentrations to all-cause and coronary heart disease (CHD) mortality, we analyzed the prospective 53-year follow-up of 1,905 men measured for lipoprotein mass concentrations by analytic ultracentrifugation between 1954 and 1957. Cause of death was determined from medical records and death certifi cates before 1979 and from National Death Index death diagnoses thereafter. Of the 1,329 men (69.8%) who died through 2008 , CHD was listed as a contributing cause of death for 409 men, including 113 deaths from premature CHD (age р 65 years). When adjusted for age, the risk associated with the lowest HDL2 quartile increased 22% for all-cause ( P = 0.001), 63% for total CHD ( P < 10 ؊ 5 ), and 117% for premature CHD mortality ( P = 0.0001). When adjusted for standard risk factors (age, total cholesterol, blood pressure, BMI, smoking) and the lowest HDL3 quartile, the corresponding risk increases were 14% ( P = 0.05), 38% ( P = 0.004), and 62% ( P = 0.02), respectively. Men with HDL3 р 25 th percentile had 28% greater ...